Proteomic Studies on Low- and High-Grade Human Brain Astrocytomas

Abstract

Human brain astrocytomas range from the indolent low-grade to the highly infiltrating and aggressive high-grade form, also known as glioblastoma multiforme. The extensive heterogeneity of astrocytic tumors complicates their pathological classification. In this study, we compared the protein pattern of low-grade fibrillary astrocytomas to that of glioblastoma multiforme by 2D electrophoresis. The level of most proteins remains unchanged between the different grade tumors and only few differences are reproducibly observable. Fifteen differentially expressed proteins, as well as seventy conserved spots, were identified by mass spectrometry. Western and immnunohistochemical analysis confirmed the differential expression of the identified proteins. These data provide an initial reference map for brain gliomas. Among the proteins more highly expressed in glioblastoma multiforme, we found peroxiredoxin 1 and 6, the transcription factor BTF3, and alpha-B-crystallin, whereas protein disulfide isomerase A3, the catalytic subunit of the cAMP-dependent protein kinase, and the glial fibrillary acidic protein are increased in low-grade astrocytomas. Our findings contribute to deepening our knowledge of the factors that characterize this class of tumors and, at the same time, can be applied toward the development of novel molecular biomakers potentially useful for an accurate classification of the grade of astrocytomas.

Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells

“…. 11 In cancer, BTF3 is found to be overexpressed in glioblastoma multiforme 12 and sporadic colorectal cancer. 13 We have previously identified BTF3 as a differentially expressed gene in PDAC and chronic pancreatitis (CP).…”

Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients

“…From these reports and our former study, Prdx1 appears to have a possible correlation with an anti-tumor effect by producing epigenetic changes in cancer patients. On the other hand, some researchers have mentioned that this protein may be involved with cell proliferation and tumor growth in several kinds of solid cancers (11)(12)(13)(14)(15).…”

“…From these reports and our former study, Prdx1 appears to have a possible correlation with an anti-tumor effect by producing epigenetic changes in cancer patients. On the other hand, some researchers have mentioned that this protein may be involved with cell proliferation and tumor growth in several kinds of solid cancers (11)(12)(13)(14)(15).In order to contribute to the controversial discussion about the influence of Prdx1 expression in malignant tumors, we examined the expression of this protein in 114 cases of ESCC by immunohistochemistry and evaluated the correlations with the clinical parameters of ESCC to determine whether or not the expression of PrdxI in ESCC plays an important role in tumor progression. ONCOLOGY REPORTS 18: 867-871, 2007 867 Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients ISAMU HOSHINO, HISAHIRO MATSUBARA, YASUNORI AKUTSU, TAKANORI NISHIMORI, YASUO YONEYAMA, KENTARO MURAKAMI, HARUHITO SAKATA, KAZUYUKI MATSUSHITA and TAKENORI OCHIAI…”

Glioma Proteomics: Methods and Current Perspective

“…High levels expression of four proteins-VREB1, GRP78, RhoA and Rac1 and lower expression of enolase in grade IV tumors compared to lower grade tumors was also confirmed by immunohistochemistry. In another attempt to identify differentially expressed proteins between astrocytoma grades, 10 grade II and 10 grade IV samples were analyzed by 2DE followed by mass spectrometry, which resulted in the identification of 15 differentially expressed proteins (Odreman et al, 2005). These findings were subsequently validated by western blotting and immunohistochemcial staining.…”